Botox Approved in US

Botox Gets US FDA Approval for Chronic Migraine

Earlier this month, the FDA granted approval to Botox® (onabotulinumtoxinA is the generic name) for the treatment of chronic migraine.  Treatment options that have been well studied are limited for sufferers of chronic migraine, who have 15 or more headache days a month.

The study leading to approval of this treatment involved a protocol of 31 injections in seven areas of the head and neck. Headaches were reduced by an average of 2.3 days a month. Injections of Botox are necessary four times a year.

Treatment with botulinum toxins has been used for a variety of neurologic conditions for many years, and has been helpful through its ability to selectively paralyze muscle fibers and the nerves that serve them by preventing the release of neurotransmitter chemicals. It is less certain how it works in the prevention of pain, but may prevent the release of other neurotransmitters that are important in transmitting pain messages to the brain.

Chronic migraine affects 3.2 million Americans.